PAION Pharma launched Byfavo® with the active ingredient remimazolam in Germany on January 1, 2026. New active ingredients are a rarity in anesthesiology. With remimazolam, a new generation of intravenous anesthetics is now available for the first time in many years.
To mark the market launch, we held a digital press conference in January 2026. Representatives from leading medical trade media took part in the event. The interest shown by the trade press underlines the relevance of the launch for the German market.
Remimazolam is approved in the European Union as Byfavo® 20 mg for procedural sedation and as Byfavo® 50 mg for intravenous induction and maintenance of general anesthesia in adult patients.
Members of the professional community can find further information on Byfavo® in our protected specialist area on our website.